Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin

Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/− mice

(2010) Jiumei Cao et al.   HUMAN MOLECULAR GENETICS

MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice

(2010) Denghong Zhang et al.   JOURNAL OF CLINICAL INVESTIGATION

Mammalian Target of Rapamycin Is a Critical Regulator of Cardiac Hypertrophy in Spontaneously Hypertensive Rats

(2009) Will Soesanto et al.   HYPERTENSION

Cardiac-specific Deletion of LKB1 Leads to Hypertrophy and Dysfunction

(2009) Yasumasa Ikeda et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure

(2009) Andrew M. Siedlecki et al.   KIDNEY INTERNATIONAL

Renal and liver tumors in Tsc2+/- mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

(2009) G. A. Finlay et al.   MOLECULAR CANCER THERAPEUTICS

The TSC1–TSC2 complex: a molecular switchboard controlling cell growth

(2008) Jingxiang Huang et al.   BIOCHEMICAL JOURNAL

Sirolimus treatment of left ventricular hypertrophy: who, and when?

(2008) M. G. Crespo-Leiro et al.   EUROPEAN HEART JOURNAL

Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients

(2008) S. S. Kushwaha et al.   EUROPEAN HEART JOURNAL

Cardiac Restricted Overexpression of Kinase-dead Mammalian Target of Rapamycin (mTOR) Mutant Impairs the mTOR-mediated Signaling and Cardiac Function

(2008) Wei-Hua Shen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2

(2008) J. Huang et al.   MOLECULAR AND CELLULAR BIOLOGY